Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2021-08-12 Interim / Quarterly Rep…
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation titled 'Half year results 2021' for Biotest AG. It contains comprehensive financial data, including income statements, balance sheet summaries, segment performance, and R&D updates for the first half of the fiscal year. It is not a mere announcement (RPA) or a transcript (CT), but rather a substantive report on interim financial performance and business strategy, fitting the definition of an Interim/Quarterly Report. H2 2021
2021-08-12 German
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation titled 'Half year results 2021' for Biotest AG. It contains comprehensive financial data, including income statements, balance sheet summaries, segment performance, and R&D updates for the first half of the fiscal year. It is not a mere announcement (RPA) or a transcript (CT), but rather a substantive report on interim financial performance and business strategy, fitting the definition of an Interim/Quarterly Report. H2 2021
2021-08-12 English
Half-yearly financial report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half-Year Report 2021' for Biotest AG. It contains comprehensive financial data, including a consolidated statement of income, balance sheet, cash flow statement, and an interim management report for the period ending 30 June 2021. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H2 2021
2021-08-12 German
Biotest AG: Biotest proves the mode of action of trimodulin for the treatment of COVID-19
Regulatory Filings Classification · 99% confidence The document is a press release dated August 3, 2021, announcing research updates regarding Biotest AG's product, trimodulin, for COVID-19 treatment. It details preclinical study publications and mentions upcoming Phase II clinical trial results. The structure, use of 'DGAP-News', 'PRESS RELEASE', and the focus on a specific corporate development (research update) strongly suggest this is a general corporate announcement disseminated via a regulatory news service. Since it is not a full financial report (10-K, IR), a specific earnings release (ER), or a formal proxy/voting document, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such corporate news releases that don't fit other specific categories, especially when disseminated through services like DGAP.
2021-08-03 English
Biotest AG: Biotest AG opens 11th plasma collection centre in Hungary
Regulatory Filings Classification · 100% confidence The document is a short press release dated July 20, 2021, announcing a specific operational update: the opening of a new plasma collection center in Hungary. It contains keywords like "DGAP-News," "PRESS RELEASE," and is disseminated via DGAP, which often handles general corporate news. The content is not a comprehensive financial report (like 10-K or IR), nor is it a transcript (CT) or a formal voting result (DVA). It is a specific operational announcement that doesn't fit neatly into the primary financial categories (ER, IR, CAP, DIV). Since it is a general corporate news item disseminated through a regulatory news service (DGAP) and doesn't match any other specific category (like DIRS, MANG, or LTR), the most appropriate fallback category is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements.
2021-07-20 English
Ergänzung der Veröffentlichung vom 02.06.2021
AGM Information Classification · 99% confidence The document text explicitly mentions 'Gewinnverwendungsbeschluss' (Resolution on the Appropriation of Profits) and details the decision made by the 'ordentliche Hauptversammlung' (Annual General Meeting) regarding the distribution of the 2020 fiscal year profit, specifically declaring a dividend of EUR 0.04 per preferred share. This content directly relates to the outcome of a shareholder vote concerning profit allocation, which aligns perfectly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to an AGM, the core content is the result of the vote, not the general AGM presentation (AGM-R) or a dividend notice (DIV), as it stems from the formal resolution passed at the meeting.
2021-07-14 German

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.